| Item Type | Name |
|
Concept
|
Carcinoma
|
|
Concept
|
Palliative Care
|
|
Concept
|
Patient Care Team
|
|
Concept
|
Preoperative Care
|
|
Concept
|
Thrombocytopenia
|
|
Concept
|
Thiotepa
|
|
Concept
|
Time Factors
|
|
Concept
|
Tomography, X-Ray Computed
|
|
Concept
|
Tissue Donors
|
|
Concept
|
Troponin
|
|
Concept
|
Practice Guidelines as Topic
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Health Care Rationing
|
|
Concept
|
Stem Cell Transplantation
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
CD8-Positive T-Lymphocytes
|
|
Concept
|
Transplantation Conditioning
|
|
Concept
|
Venous Thromboembolism
|
|
Concept
|
Tumor Burden
|
|
Concept
|
Triazoles
|
|
Concept
|
Tumor Lysis Syndrome
|
|
Concept
|
Lymphoma, T-Cell
|
|
Concept
|
Standard of Care
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Receptors, Antigen, T-Cell
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Translocation, Genetic
|
|
Concept
|
Transplantation, Autologous
|
|
Concept
|
Transplantation, Homologous
|
|
Concept
|
Maximum Tolerated Dose
|
|
Academic Article
|
Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.
|
|
Academic Article
|
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.
|
|
Academic Article
|
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
|
|
Academic Article
|
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia.
|
|
Academic Article
|
Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.
|
|
Academic Article
|
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
|
|
Academic Article
|
Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
|
|
Academic Article
|
Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
|
|
Academic Article
|
Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
|
|
Academic Article
|
Double hit and double expressors in lymphoma: Definition and treatment.
|
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
|
Academic Article
|
Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma.
|
|
Academic Article
|
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
|
|
Academic Article
|
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
|
|
Academic Article
|
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas.
|
|
Academic Article
|
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
|
|
Academic Article
|
Advances in CAR T-Cell Therapy for Aggressive B-NHL.
|
|
Academic Article
|
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
|
|
Academic Article
|
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.
|
|
Academic Article
|
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials.
|
|
Academic Article
|
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
|
|
Academic Article
|
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
|
|
Academic Article
|
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
|
|
Academic Article
|
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
|
|
Academic Article
|
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
|
|
Academic Article
|
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
|
|
Academic Article
|
Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents.
|
|
Academic Article
|
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
|
|
Academic Article
|
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
|
|
Academic Article
|
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
|
|
Academic Article
|
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
|
|
Academic Article
|
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
|
|
Academic Article
|
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
|
|
Academic Article
|
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
|
|
Academic Article
|
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.
|
|
Academic Article
|
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
|
|
Concept
|
Cell- and Tissue-Based Therapy
|
|
Academic Article
|
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
|
|
Academic Article
|
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
|
|
Academic Article
|
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
|
|
Academic Article
|
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
|
|
Academic Article
|
Infectious complications of car T-cell therapy: A longitudinal risk model.
|
|
Academic Article
|
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
|
|
Academic Article
|
If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary.
|
|
Academic Article
|
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
|
|
Academic Article
|
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
|
|
Academic Article
|
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
|
|
Academic Article
|
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.
|
|
Academic Article
|
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
|
|
Academic Article
|
Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.
|
|
Academic Article
|
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.
|
|
Academic Article
|
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.
|
|
Academic Article
|
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.
|
|
Academic Article
|
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
|
|
Academic Article
|
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
|
|
Academic Article
|
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
|
|
Academic Article
|
BsAbs before CD19 CAR-T: full speed ahead!
|
|
Academic Article
|
Correction to: Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.
|
|
Academic Article
|
Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel.
|